Influenza vaccine effectiveness against A(H3N2) during the delayed 2021/22 epidemic in Canada.

Shinhye Kim,Erica Sy Chuang,Suzana Sabaiduc,Romy Olsha, Samantha E Kaweski,Nathan Zelyas,Jonathan B Gubbay,Agatha N Jassem,Hugues Charest,Gaston De Serres,James A Dickinson,Danuta M Skowronski

Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin（2022）

引用 11|浏览6

暂无评分

摘要

Influenza virus circulation virtually ceased in Canada during the COVID-19 pandemic, re-emerging with the relaxation of restrictions in spring 2022. Using a test-negative design, the Canadian Sentinel Practitioner Surveillance Network reports 2021/22 vaccine effectiveness of 36% (95% CI: -38 to 71) against late-season illness due to influenza A(H3N2) clade 3C.2a1b.2a.2 viruses, considered antigenically distinct from the 3C.2a1b.2a.1 vaccine strain. Findings reinforce the World Health Organization's decision to update the 2022/23 northern hemisphere vaccine to a more representative A(H3N2) clade 3C.2a1b.2a.2 strain.

查看译文

关键词

A(H3N2),Influenza,clade,observational study,test-negative design,vaccine effectiveness

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要